MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.
Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.
MacroGenics, Inc. outlines its oncology-focused business, pipeline and key partnerships in this annual report. The company develops antibody-based cancer therapeutics, including antibody-drug conjugates and multi-specific antibodies generated from its DART and TRIDENT platforms, and operates a commercial-scale cGMP manufacturing facility in Maryland.
MacroGenics has contributed three FDA-approved medicines now marketed by partners and reports over $1.6 billion in cumulative non-dilutive collaboration funding since inception. It details clinical progress for wholly owned candidates MGC026, MGC028 and lorigerlimab, as well as partnered CD123×CD3 DART MGD024 with Gilead. The report also highlights sizeable milestone inflows and royalty monetizations tied to TZIELD and ZYNYZ, new manufacturing and supply agreements, and explains major risks, including funding needs, strong competition and recent safety-related setbacks such as a partial FDA clinical hold on the LINNET study of lorigerlimab and discontinuation of vobra duo development.
MacroGenics, Inc. reported that board member Jay Siegel, M.D. has informed the board that he will not stand for re-election as a Class I director at the company’s 2026 Annual Meeting of Stockholders. The company states that his decision is for personal reasons and not due to any disagreement regarding its operations, policies, or practices. MacroGenics thanks Dr. Siegel for his contributions to the company.
MacroGenics, Inc. reported that the U.S. Food and Drug Administration has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers. Under this action, enrollment of new patients is paused, while existing participants may continue to receive the study drug.
The hold follows recent serious safety events in four patients, including Grade 4 thrombocytopenia in two cases, Grade 4 myocarditis in one case, and Grade 4 neutropenia with concurrent septic shock in one case that progressed to a Grade 5 event. To date, 41 participants have been dosed at 6 mg/kg every three weeks across platinum-resistant ovarian cancer and clear cell gynecologic cancer cohorts.
The LINNET trial uses a Simon two-stage design in platinum-resistant ovarian cancer, with a potential expansion from about 20 to 40 patients if a predefined activity threshold is reached, and includes up to 20 patients with clear cell gynecologic cancer. MacroGenics states it is committed to working closely with the FDA to resolve the partial hold and aims to resume enrollment as soon as conditions allow.
Armistice Capital and Steven Boyd reported beneficial ownership of 6,324,000 shares of MACROGENICS INC, representing 9.99% of the outstanding common stock as of 12/31/2025. The filing states Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice Capital exercises shared voting and dispositive power over those securities under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, is disclosed as potentially deemed to beneficially own the shares. The Master Fund is identified as the party with the economic right to dividends and sale proceeds.
MacroGenics senior vice president and CSO Ezio Bonvini reported equity grants and related share activity. On February 12, 2026 he received 31,250 restricted stock units and options for 187,500 shares at $1.71 per share, expiring February 12, 2036. On February 15, 2026 16,665 RSUs converted into common stock and 6,433 shares were withheld at $1.71 for taxes. After these transactions he directly holds 145,799 common shares and 31,250 RSUs.
MacroGenics (MGNX) vice president Beth Ann Smith reported several equity compensation transactions. On February 12, 2026, she received a grant of 15,625 restricted stock units (RSUs) and 93,750 employee stock options with an exercise price of $1.71 per share.
On February 15, 2026, 1,095 RSUs converted into the same number of common shares, increasing her directly held common stock to 13,204 shares before tax settlement. To cover tax obligations, 423 common shares were withheld at $1.71 per share, leaving her with 12,781 common shares held directly after the transactions.
MacroGenics SVP and CFO James Karrels reported multiple equity compensation moves. On February 15, 2026, he exercised 14,999 restricted stock units, receiving the same number of common shares at an exercise price of $0. In a related tax-withholding transaction coded "F," 5,790 common shares were disposed of at $1.71 per share, leaving him with 206,037 common shares held directly.
Earlier, on February 12, 2026, he was granted an employee stock option for 150,000 shares at an exercise price of $1.71 per share, expiring on February 12, 2036. He also received a new grant of 25,000 restricted stock units, each RSU representing a right to one share, scheduled to vest 33% one year after grant and 33% each year thereafter.
MacroGenics executive Jeffrey Stuart Peters, Senior VP, General Counsel and Secretary, reported several equity compensation moves. On February 15, 2026, 13,332 restricted stock units were exercised into common shares, and 5,147 of those shares were withheld at $1.71 per share to cover tax obligations, leaving 31,105 common shares held directly.
Earlier, on February 12, 2026, Peters received a grant of 150,000 employee stock options with a $1.71 exercise price, expiring on February 12, 2036, and a separate grant of 25,000 restricted stock units. The RSUs are scheduled to vest in three equal annual installments, each representing the right to receive one share of MacroGenics common stock.
MacroGenics senior vice president Thomas Spitznagel reported multiple equity transactions in February 2026. On February 12, 2026, he received 25,000 restricted stock units and an employee stock option for 150,000 shares of common stock at an exercise price of $1.71 per share.
On February 15, 2026, he exercised 13,332 restricted stock units, converting them into the same number of common shares, and 5,520 shares were disposed of at $1.71 per share to cover taxes or exercise costs. After these transactions, he directly owned 38,543 common shares of MacroGenics.
MacroGenics Inc. President and CEO Eric Blasius Risser reported several equity compensation moves. On February 12, 2026, he received 100,000 restricted stock units and 595,000 employee stock options, each tied to future vesting and exercisability conditions described in the filing.
On February 15, 2026, he exercised 16,665 restricted stock units, receiving the same number of common shares, and then disposed of 6,433 shares at $1.71 per share to cover tax obligations. After these transactions he directly owned 77,169 common shares of MacroGenics.